Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABFRA:A39 +0.34%72 5-Year Yield-on-Cost % is 4.75 as of Jul. 29, 2026, which is 112% above its 10-year median of 2.24. GuruFocus rates FRA:A39 with a GF Score™ of 72/100 and a GF Value™ of €3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 69 Medical Distribution companies, Arjo AB ranks better than 63.77% on this metric.
Arjo AB's yield on cost for the quarter that ended in Jun. 2026 was 4.75.
The historical rank and industry rank for Arjo AB's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:A39'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.88 Med: 2.24 Max: 5.12
Current: 4.75
During the past 13 years, Arjo AB's highest Yield on Cost was 5.12. The lowest was 0.88. And the median was 2.24.
FRA:A39's 5-Year Yield-on-Cost % is ranked better than 63.77% of 69
companies
in the Medical Distribution industry
Industry Median: 3.09
vs FRA:A39: 4.75
Arjo AB (FRA:A39) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Arjo AB 5-Year Yield-on-Cost % Related Terms
FRA:A39 vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Arjo AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Arjo AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Arjo AB is calculated as
Arjo AB (FRA:A39) has a 5-Year Yield-on-Cost % of 4.75 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arjo AB and its competitors. This is 112% above median its historical median of 2.24. Over the past decade, Arjo AB's 5-Year Yield-on-Cost % has ranged from 0.88 to 5.12. According to the industry distribution chart, Arjo AB ranks #25 out of 69 companies in the Medical Distribution industry, placing it in the top 36.2%.
Is Arjo AB's 5-Year Yield-on-Cost % too high?
Arjo AB's current 5-Year Yield-on-Cost % of 4.75 is 112% above median its 10-year median of 2.24. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 5.12. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.09. Arjo AB's value of 4.75 is 53.7% above this industry median. Based on the distribution chart, Arjo AB ranks #25 out of 69 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arjo AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #25 out of 69 companies for 5-Year Yield-on-Cost %. This puts Arjo AB in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 3.09. Arjo AB's value of 4.75 is 53.7% above this benchmark. Historically, Arjo AB's own 5-Year Yield-on-Cost % has ranged from 0.88 to 5.12 over the past decade. While the company's 10-year median is 2.24 vs. the industry median of 3.09, Arjo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.09, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current 5-Year Yield-on-Cost % of 4.75 is 53.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current 5-Year Yield-on-Cost % is 4.75, which is 112% above median its own 10-year median of 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.06, compared to a current price of €2.38 — trading 22.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.75, which is 112% above median its 10-year median of 2.24 and 53.7% above the Medical Distribution industry median of 3.09. Arjo AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current 5-Year Yield-on-Cost % is 4.75 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.38 is trading 22.4% below its estimated GF Value™ of €3.06.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for FRA:A39:
5-Year Yield-on-Cost %: 4.75 (112% above median its 10-year median of 2.24)
GF Value™: €3.06 vs. price of €2.38 (22.4% below fair value)
Industry Position: 53.7% above the Medical Distribution median (#25 of 69)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
72GF Score
Get the complete analysis for FRA:A39
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
